113 related articles for article (PubMed ID: 15746176)
1. Antibody phage display technologies with special reference to angiogenesis.
Smith J; Kontermann RE; Embleton J; Kumar S
FASEB J; 2005 Mar; 19(3):331-41. PubMed ID: 15746176
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
Takahashi N; Haba A; Matsuno F; Seon BK
Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
[TBL] [Abstract][Full Text] [Related]
3. Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105).
Nettelbeck DM; Miller DW; Jérôme V; Zuzarte M; Watkins SJ; Hawkins RE; Müller R; Kontermann RE
Mol Ther; 2001 Jun; 3(6):882-91. PubMed ID: 11407902
[TBL] [Abstract][Full Text] [Related]
4. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
Seon BK; Matsuno F; Haruta Y; Kondo M; Barcos M
Clin Cancer Res; 1997 Jul; 3(7):1031-44. PubMed ID: 9815781
[TBL] [Abstract][Full Text] [Related]
5. Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells.
She X; Matsuno F; Harada N; Tsai H; Seon BK
Int J Cancer; 2004 Jan; 108(2):251-7. PubMed ID: 14639611
[TBL] [Abstract][Full Text] [Related]
6. Production and characterization of a high-affinity nanobody against human endoglin.
Ahmadvand D; Rasaee MJ; Rahbarizadeh F; Mohammadi M
Hybridoma (Larchmt); 2008 Oct; 27(5):353-60. PubMed ID: 18847348
[TBL] [Abstract][Full Text] [Related]
7. Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2.
Miao HQ; Hu K; Jimenez X; Navarro E; Zhang H; Lu D; Ludwig DL; Balderes P; Zhu Z
Biochem Biophys Res Commun; 2006 Jun; 345(1):438-45. PubMed ID: 16682007
[TBL] [Abstract][Full Text] [Related]
8. CD105 is important for angiogenesis: evidence and potential applications.
Duff SE; Li C; Garland JM; Kumar S
FASEB J; 2003 Jun; 17(9):984-92. PubMed ID: 12773481
[TBL] [Abstract][Full Text] [Related]
9. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies.
Matsuno F; Haruta Y; Kondo M; Tsai H; Barcos M; Seon BK
Clin Cancer Res; 1999 Feb; 5(2):371-82. PubMed ID: 10037187
[TBL] [Abstract][Full Text] [Related]
10. Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain.
Carnemolla B; Neri D; Castellani P; Leprini A; Neri G; Pini A; Winter G; Zardi L
Int J Cancer; 1996 Nov; 68(3):397-405. PubMed ID: 8903484
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.
Zhu Z; Hattori K; Zhang H; Jimenez X; Ludwig DL; Dias S; Kussie P; Koo H; Kim HJ; Lu D; Liu M; Tejada R; Friedrich M; Bohlen P; Witte L; Rafii S
Leukemia; 2003 Mar; 17(3):604-11. PubMed ID: 12646950
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody.
Tanaka F; Otake Y; Yanagihara K; Kawano Y; Miyahara R; Li M; Yamada T; Hanaoka N; Inui K; Wada H
Clin Cancer Res; 2001 Nov; 7(11):3410-5. PubMed ID: 11705856
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis and metastasis marker of human tumors.
Seon BK; Takahashi N; Haba A; Matsuno F; Haruta Y; She XW; Harada N; Tsai H
Rinsho Byori; 2001 Oct; 49(10):1005-13. PubMed ID: 11769465
[TBL] [Abstract][Full Text] [Related]
14. Targeting of vasculature in cancer and other angiogenic diseases.
Kumar S; Li C
Trends Immunol; 2001 Mar; 22(3):129. PubMed ID: 11334027
[No Abstract] [Full Text] [Related]
15. Identification of novel neutralizing single-chain antibodies against vascular endothelial growth factor receptor 2.
Erdag B; Balcioglu BK; Bahadir AO; Serhatli M; Kacar O; Bahar A; Seker UO; Akgun E; Ozkan A; Kilic T; Tamerler C; Baysal K
Biotechnol Appl Biochem; 2011; 58(6):412-22. PubMed ID: 22172104
[TBL] [Abstract][Full Text] [Related]
16. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature.
Korpanty G; Carbon JG; Grayburn PA; Fleming JB; Brekken RA
Clin Cancer Res; 2007 Jan; 13(1):323-30. PubMed ID: 17200371
[TBL] [Abstract][Full Text] [Related]
17. Cell selection and characterization of a novel human endothelial cell specific nanobody.
Ahmadvand D; Rasaee MJ; Rahbarizadeh F; Kontermann RE; Sheikholislami F
Mol Immunol; 2009 May; 46(8-9):1814-23. PubMed ID: 19249099
[TBL] [Abstract][Full Text] [Related]
18. Isolation of endothelial cell-specific human antibodies from a novel fully synthetic scFv library.
Völkel T; Müller R; Kontermann RE
Biochem Biophys Res Commun; 2004 Apr; 317(2):515-21. PubMed ID: 15063787
[TBL] [Abstract][Full Text] [Related]
19. Generation of Potent Anti-Vascular Endothelial Growth Factor Neutralizing Antibodies from Mouse Phage Display Library for Cancer Therapy.
Lai YD; Wu YY; Tsai YJ; Tsai YS; Lin YY; Lai SL; Huang CY; Lok YY; Hu CY; Lai JS
Int J Mol Sci; 2016 Feb; 17(2):214. PubMed ID: 26861297
[TBL] [Abstract][Full Text] [Related]
20. [Endoglin (CD105)--a target for visualization and anti-angiogenic therapy for malignant tumors].
Smirnov IV; Gryazeva IV; Samoilovich MP; Klimovich VB
Vopr Onkol; 2015; 61(6):898-907. PubMed ID: 26995976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]